Neumora Therapeutics, Inc. (NMRA) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Numora Therapeutics (NMRA) Q4 2025: NMRA 215 Clinic Entry Delayed to 2027 After Toxicology Setback
  March 30, 2026
• Numora Therapeutics (NMRA) Q2 2025: Cash Runway Extends Into 2027 as Six Clinical Catalysts Approach
  August 06, 2025
• Numora Therapeutics (NMRA) Q1 2025: $125M Debt Facility Extends Runway Past Key Clinical Milestones
  July 07, 2025

Browse all companies